Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model

Journal of Hepatology

Volumn 59, Issue 2, 2013, Pages 318-326

  Robinson, S M ^a,b   Mann, J ^a   Vasilaki, A ^c   Mathers, J ^a   Burt, A D ^d   Oakley, F ^a   White, S A ^a,b   Mann, D A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Keywords Sinusoidal obstruction syndrome Oxaliplatin Colorectal liver metastases Chemotherapy induced liver injury

Indexed keywords

ACETYLCYSTEINE; BLOOD CLOTTING FACTOR 10; BUTYLATED HYDROXYANISOLE; FLUOROURACIL; FOLINIC ACID; GUAIACOL; OXALIPLATIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENDOTHELIUM LESION; EXPERIMENTAL MODEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL; LIVER FIBROSIS; LIVER SINUSOID; LIVER VENOOCCLUSIVE DISEASE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SENESCENCE; SPLEEN; UPREGULATION;

ΓH2AX; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALP; ALT; ASPARTATE AMINOTRANSFERASE; AST; BHA; BUTYLATED HYDROXYANISOLE; CHEMOKINE (C-X-C MOTIF) LIGAND 1/2; CHEMOTHERAPY INDUCED LIVER INJURY; COLORECTAL LIVER METASTASES; CRLM; CXCL1/2; GAPDH; GYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE; H&E; HAEMATOXYLIN AND EOSIN; HIGH POWERED FIELD; HPF; I.P.; IL-6; INTERLEUKIN 6; INTRAPERITONEAL; MCP1; MONOCYTE CHEMOTACTIC PROTEIN-1; N-ACETYLCYSTEINE; NAC; NAD(P)H DEHYDROGENASE 1; NQO1; NRF2; NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2; OXALIPLATIN; PAI-1; PAR 1/2; PCNA; PHOSPHORYLATED FORM OF THE H2A HISTONE FAMILY, MEMBER X; PLASMINOGEN ACTIVATIOR INHIBITOR 1; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEASE ACTIVATED RECEPTOR 1/2; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; SINUSOIDAL OBSTRUCTION SYNDROME; SOS; STAT3; THIOREDOXIN 1; TXN1; VASCULAR ENDOTHELIAL GROWTH FACTOR A/B/C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1/2; VEGF-A/B/C; VEGFR-1/2; VON WILLEBRAND FACTOR; VWF;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; CELL CYCLE; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOKINES; DISEASE MODELS, ANIMAL; FLUOROURACIL; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFLAMMATION MEDIATORS; LEUCOVORIN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; OXIDATIVE STRESS; SERPIN E2; THROMBOSIS;

EID: 84880271807     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.04.014     Document Type: Article

References (48)

1. T.S. Maughan, R.A. Adams, C.G. Smith, A.M. Meade, M.T. Seymour, and R.H. Wilson Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
2. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [see comment] N Engl J Med 350 2004 2335 2342
3. L. Rubbia-Brandt, V. Audard, P. Sartoretti, A.D. Roth, C. Brezault, and M. Le Charpentier Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann Oncol 15 2004 460 466
4. C. Hubert, C. Fervaille, C. Sempoux, Y. Horsmans, Y. Humblet, and J.P. Machiels Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases Surgery 147 2010 185 194
5. J.N. Vauthey, T.M. Pawlik, D. Ribero, T.T. Wu, D. Zorzi, and P.M. Hoff Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J Clin Oncol 24 2006 2065 2072
6. D. Tamandl, M. Klinger, S. Eipeldauer, B. Herberger, K. Kaczirek, and B. Gruenberger Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy Ann Surg Oncol 18 2011 421 430
7. S.M. Robinson, C.H. Wilson, A.D. Burt, D.M. Manas, and S.A. White Chemotherapy associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis Ann Surg Oncol 19 13 2012 4287 4299
8. M.M. Aloysius, A.M. Zaitoun, I.J. Beckingham, K.R. Neal, G.P. Aithal, and E.M. Bessell The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study Virchows Arch 451 2007 943 948
9. H. Nakano, E. Oussoultzoglou, E. Rosso, S. Casnedi, M.P. Chenard-Neu, and P. Dufour Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann Surg 247 2008 118 124
10. O. Soubrane, A. Brouquet, S. Zalinski, B. Terris, C. Brezault, and V. Mallet Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome Ann Surg 251 2010 454 460
11. C.P. Vreuls, M.A. Van Den Broek, A. Winstanley, G.H. Koek, E. Wisse, and C.H. Dejong Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases Histopathology 61 2 2012 314 318
12. D. Keizman, N. Maimon, M. Ish-Shalom, D. Buchbut, M. Inbar, and B. Klein An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate Cancer 116 2010 251 255
13. S. Cao, C. Frank, and Y.M. Rustum Role of fluoropyrimidine Schedule and (6R, S)leucovorin dose in a preclinical animal model of colorectal carcinoma J Natl Cancer Inst 88 1996 430 436
14. N.A. Boughattas, F. Levi, C. Fournier, G. Lemaigre, A. Roulon, and B. Hecquet Circadian rhythm in toxicities and tissue uptake of 1,2- diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice Cancer Res 49 1989 3362 3368
15. M.E. Anderson Measurement of antioxidants: glutathione N.A. Punchard, F.J. Kelly, Free radicals, a practical approach 1996 IRL Press Oxford 213 226
16. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J Biol Chem 193 1951 265 275
17. L. Rubbia-Brandt, V. Audard, P. Sartoretti, A.D. Roth, C. Brezault, and M. Le Charpentier Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann Oncol 15 2004 460 466
18. M. Collado, M.A. Blasco, and M. Serrano Cellular senescence in cancer and aging Cell 130 2007 223 233
19. L. Rubbia-Brandt, S. Tauzin, C. Brezault, C. Delucinge-Vivier, P. Descombes, and B. Dousset Gene expression profiling provides insights into pathways of oxaliplatin related sinusoidal obstruction syndrome in humans Mol Cancer Ther 10 2011 687 696
20. R.M. Kortlever, and R. Bernards Senescence, wound healing and cancer: the PAI-1 connection Cell Cycle 5 2006 2697 2703
21. R.M. Kortlever, P.J. Higgins, and R. Bernards Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence Nat Cell Biol 8 2006 877 884
22. F. Rodier, J. Campisi, and D. Bhaumik Two faces of p53: aging and tumor suppression Nucleic Acids Res 35 2007 7475 7484
23. M. Remberger, and O. Ringden Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver Eur J Haematol 59 1997 254 262
24. T. Kuilman, C. Michaloglou, L.C. Vredeveld, S. Douma, R. van Doorn, and C.J. Desmet Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network Cell 133 2008 1019 1031
25. C. Drucker, J. Gewiese, S. Malchow, J. Scheller, and S. Rose-John Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration J Autoimmun 34 2009 29 37
26. H. Wang, F. Lafdil, X. Kong, and B. Gao Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target Int J Biol Sci 7 2011 536 550
27. D.M. Kweekel, H. Gelderblom, and H.J. Guchelaar Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy Cancer Treat Rev 31 2005 90 105
28. X. Wang, G.C. Kanel, and L.D. DeLeve Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat Hepatology 31 2000 428 434
29. K.R. Martin, C. Trempus, M. Saulnier, F.W. Kari, J.C. Barrett, and J.E. French Dietary N-acetyl-l-cysteine modulates benzo[a]pyrene-induced skin tumors in cancer-prone p53 haploinsufficient Tg.AC (v-Ha-ras) mice Carcinogenesis 22 2001 1373 1378
30. L.G. Higgins, and J.D. Hayes Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents Drug Metab Rev 43 2011 92 137
31. K. Nakamura, E. Hatano, M. Narita, A. Miyagawa-Hayashino, Y. Koyama, and H. Nagata Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9 J Hepatol 57 2012 1037 1043
32. M.J. Overman, D.M. Maru, C. Charnsangavej, E.M. Loyer, H. Wang, and P. Pathak Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury J Clin Oncol 28 2010 2549 2555
33. S.L. Friedman Liver fibrosis - from bench to bedside J Hepatol 38 2003 S38 S53
34. L.D. DeLeve, R.S. McCuskey, X. Wang, L. Hu, M.K. McCuskey, and R.B. Epstein Characterization of a reproducible rat model of hepatic veno-occlusive disease Hepatology 29 1999 1779 1791
35. A.E. Schultze, and R.A. Roth Chronic pulmonary hypertension - the monocrotaline model and involvement of the hemostatic system J Toxicol Environ Health B Crit Rev 1 1998 271 346
36. R.A. Roth, and J.F. Reindel Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite Adv Exp Med Biol 283 1991 477 487
37. M.F. McCarty, J. Barroso-Aranda, and F. Contreras Genistein and phycocyanobilin may prevent hepatic fibrosis by suppressing proliferation and activation of hepatic stellate cells Med Hypotheses 72 2009 330 332
38. C. Ascencio, N. Torres, F. Isoard-Acosta, F.J. Gomez-Perez, R. Hernandez-Pando, and A.R. Tovar Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats J Nutr 134 2004 522 529
39. A.K. Ghosh, and D.E. Vaughan PAI-1 in tissue fibrosis J Cell Physiol 227 2012 493 507
40. M.J. Smilkstein, G.L. Knapp, K.W. Kulig, and B.H. Rumack Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985) N Engl J Med 319 1988 1557 1562
41. E. Balogun, M. Hoque, P. Gong, E. Killeen, C.J. Green, and R. Foresti Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element Biochem J 371 2003 887 895
42. B.B. Patel, D. Gupta, A.A. Elliott, V. Sengupta, Y. Yu, and A.P. Majumdar Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R Anticancer Res 30 2010 319 325
43. A. Brouquet, S. Benoist, C. Julie, C. Penna, A. Beauchet, and P. Rougier Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases Surgery 145 2009 362 371
44. L. Benimetskaya, S. Wu, A.M. Voskresenskiy, C. Echart, J. Zhou, and J. Shin Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease Blood 112 2008 4343 4352
45. C.J. Scotton, M.A. Krupiczojc, M. Konigshoff, P.F. Mercer, Y.C. Lee, and N. Kaminski Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury J Clin Invest 119 2009 2550 2563
46. A. Rullier, J. Gillibert-Duplantier, P. Costet, G. Cubel, V. Haurie, and C. Petibois Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis Am J Physiol Gastrointest Liver Physiol 294 2008 G226 G235
47. S. Fiorucci, E. Antonelli, E. Distrutti, B. Severino, R. Fiorentina, and M. Baldoni PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation Hepatology 39 2004 365 375
48. J. Agostini, S. Benoist, M. Seman, C. Julie, S. Imbeaud, and F. Letourneur Identification of molecular pathways involved in oxaliplatin- associated sinusoidal dilatation J Hepatol 56 2012 869 876